Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin

PURPOSE: The aromatase inactivator exemestane may cause clinical disease stabilization following progression on non-steroidal aromatase inhibitors like letrozole in patients with metastatic breast cancer, indicating that additional therapeutic effects, not necessarily related to estrogen-suppression...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahrami, Nazli, Jabeen, Shakila, Tahiri, Andliena, Sauer, Torill, Ødegård, Hilde Presterud, Geisler, Stephanie Beate, Gravdehaug, Berit, Reitsma, Laurens Cornelus, Selsås, Knut, Kristensen, Vessela, Geisler, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558290/
https://www.ncbi.nlm.nih.gov/pubmed/34554372
http://dx.doi.org/10.1007/s10549-021-06399-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558290/
https://www.ncbi.nlm.nih.gov/pubmed/34554372
http://dx.doi.org/10.1007/s10549-021-06399-x

Ejemplares similares